Introduction {#s1}
============

High-mobility group box 1 protein (HMGB1) was initially considered a nuclear protein regulating gene transcription. However, data emerging over the last decade identified its separate role as a pro-inflammatory cytokine that is released actively and passively from cells during inflammation and injury [@pone.0065994-Klune1]--[@pone.0065994-Andersson1]. According to a current classification, the immune response can be regulated by endogenous danger signals (damage-associated molecular patterns; DAMPs; alarmins) as well as exogenous pathogen-associated molecular patterns (PAMPs). In this context, HMGB1 has been identified as a *bona fide* DAMP (i.e. a mediator released during sterile inflammatory processes), as well as a mediator released during PAMP-associated inflammatory events (e.g. sepsis and septic shock), which participates in the pathogenesis of the delayed inflammatory response, organ injury and contributes to disease mortality [@pone.0065994-Klune1]--[@pone.0065994-Andersson1].

Significant work has focused on the molecular mechanisms of HMGB1 release and on the therapeutic neutralization of HMGB1, either by antibodies, or by inhibiting its binding to its receptors RAGE and TLR4 [@pone.0065994-Klune1]--[@pone.0065994-Yang1]. Several compounds have been identified that attenuate the *release of HMGB1*, including glucocorticoids, chloroquine, gold salts, nicotinic receptor agonists, ethyl pyruvate and inhibitors of poly(ADP-ribose) polymerase [@pone.0065994-Andersson1], [@pone.0065994-Ulloa1]--[@pone.0065994-Schierbeck1]. However, the inflammatory cellular responses *downstream from HMGB1* are less understood, and no systematic survey has been conducted to characterize these pathways or to identify their pharmacological modulators. One determinant of the bioactivity of extracellular HMGB1 is based on the redox status of its three conserved thiol groups. The all thiol confirmation has been show to facilitate the binding of CXCL12 to CXCR4 and thus exhibit chemokine-like properties [@pone.0065994-Venereau1]. The C23-C45 disulfide C106 thiol conformation binds to the CD14/MD2/TLR4 receptor complex [@pone.0065994-Yang2], [@pone.0065994-Kim1] and demonstrates cytokine-like properties. Using a cell-based medium-throughput screening approach, the goal of the current study was to identify drug-like compounds that down-regulate the cytokine-like activity of HMGB1-induced inflammatory processes in murine macrophages *in vitro*.

Methods {#s2}
=======

Materials and Reagents {#s2a}
----------------------

A comprehensive screening set of 5,546 compounds was gathered comprising the NIH Clinical Collection (446 phase I--III trial compounds) from BioFocus (South San Francisco, CA), the FDA Approved Library (640 FDA approved bioactive compounds) from Enzo Life Sciences (Farmingdale, NY), the Prestwick Chemical Library (1200 marketed drugs in Europe) from Prestwick Chemical (Washington, DC), the US Drug Collection (1040 clinical trial stage USP drugs), the International Drug Collection (240 compounds marketed in Europe or Asia but not in the US) and Killer Plates (160 toxic substances) from MicroSource Discovery Systems (Gaylordsville, CT), the LOPAC1280 (1280 various biologically active compounds) from Sigma-Aldrich, (Saint Louis, MO) and the Natural Products (640 natural compounds and derivatives) from TimTec LLC (Newark, DE). The compounds were dissolved at 10 mM in dimethyl-sulfoxide (DMSO) and dilutions were made either in DMSO or in phosphate-buffered saline (PBS, pH 7.4) to obtain 0.5% final DMSO concentration. HMGB1 (C23-C45 disulfide C106 thiol form) was prepared as previously described [@pone.0065994-Yang3] and diluted in OptiMEM I medium (Invitrogen, Carlsbad, CA). Unless specified otherwise, all other reagents were purchased from Sigma-Aldrich Co. (St. Louis, MO).

Cell Culture {#s2b}
------------

RAW 264.7 murine macrophages were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and maintained in Dulbecco's modified Eagle's medium (DMEM) (Hyclone, Logan, UT) containing 4.5 g/l glucose supplemented with 10% fetal bovine serum (FBS, PAA Laboratories Inc, Westborough, MA), 100 IU/ml penicillin and 100 µg/ml streptomycin (Invitrogen, Carlsbad, CA) at 37°C in 5% CO~2~ atmosphere. Prior to HMGB1 stimulation the culture medium was replaced with OptiMEM I reduced serum medium (Invitrogen, Carlsbad, CA).

Screening Assay {#s2c}
---------------

RAW 264.7 cells (100 000/well) were plated into 96-well tissue culture plates and cultured overnight. Culture medium was replaced with OptiMEM prior to adding compounds. Test compounds were supplied at 10 mM in dimethyl sulfoxide (DMSO) and were diluted in DMSO and in phosphate buffer saline (PBS) to reach 3 µM final concentration (and 0.5% DMSO) in the culture medium. The Natural Products Library was screened at 1 µg/ml final concentration. Compounds were administered in 1/20 volume 1 hour prior to HMGB1 treatment. In the combined screen the cells received additional dexamethasone (3 µM) treatment. HMGB1 was added at 5 µg/ml final concentration in 1/10 volume and the cells were incubated for 18 hours at 37°C in 5% CO~2~ atmosphere. Supernatant was collected to measure TNFα secretion and LDH release.

Viability (MTT Assay) and LDH Release Measurements {#s2d}
--------------------------------------------------

The MTT assay and LDH activity measurements were performed as previously described [@pone.0065994-Gero1]. Briefly, the cells were incubated in medium containing 0.5 mg·mL^−1^,3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Calbiochem, EMD BioSciences, San Diego, CA) for 1 hour at 37°C at 5% CO~2~ atmosphere. The converted formazan dye was dissolved in isopropanol and the absorbance was measured at 570 nm. Serial dilution of the cells was used to calculate the count of viable cells. Viability values are shown as percent values relative to vehicle treated controls. LDH release was measured by mixing cell culture supernatant (30 µl) with 100 µl LDH assay reagent containing 110 mM lactic acid, 1350 mM nicotinamide adenine dinucleotide (NAD^+^), 290 mM *N*-methylphenazonium methyl sulfate (PMS), 685 mM 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2*H*-tetrazolium chloride (INT) and 200 mM Tris (pH 8.2). The changes in absorbance were read kinetically at 492 nm for 15 min (kinetic LDH assay). LDH activity values are shown as Vmax (mOD/min).

TNFα ELISA {#s2e}
----------

Supernatant was diluted 10 times in PBS containing 1% bovine serum albumin (BSA) and the TNFα levels were determined with a commercially available ELISA kit (R&D Systems, Minneapolis, MN) on a robotic system comprising of a plate washer (EL406, Biotek, Winooski, VT), a dispenser (MicroFlo, Biotek, Winooski, VT), a pipetting station (Precision, Biotek, Winooski, VT), an incubator (Cytomat 2C, Thermo Electron Corporation, Asheville, NC) and plate reader (Synergy 2, Biotek, Winooski, VT) connected with a robotic arm (Twister II, Caliper Life Sciences Inc, Hopkinton, MA).

RNA Isolation, Gene Expression Measurements {#s2f}
-------------------------------------------

Total RNA was isolated from RAW 264.7 cells exposed to HMGB1 or vehicle for 1.5 or 6 hours using a commercial RNA purification kit (SV total RNA isolation kit, Promega, Madison, WI). 2 µg RNA was reverse transcribed using the High Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA) as previously described [@pone.0065994-Gero2]. 1 µg RNA was used according to the manufacturer's protocol for gene expression measurements using the Toll-like receptor signaling pathway real-time PCR array (PAMM-0018ZD, SA Biosciences, Frederick, MD) on CFX96 thermocycler (Biorad, Hercules, CA) and analyzed with the tool provided by SA Biosciences. A full list of the genes investigated is deposited in [Table S1](#pone.0065994.s001){ref-type="supplementary-material"}. Taqman assay for TNFα was performed using a commercial assay (TNFα assay ID: Mm00443260_g1, Life Technologies, Carlsbad, CA) using GAPDH (VIC/MGB Probe, Applied Biosystems, Foster City, CA) control as normalizer.

Western Blotting {#s2g}
----------------

Cells were lysed in denaturing loading buffer (20 mM Tris, 2% SDS, 10% glycerol, 6 M urea, 100 µg/ml bromophenol blue, 200 mM ß-mercaptoethanol) freshly supplemented with 2 mM sodium vanadate, 100 mM sodium fluoride, 20 mM beta-glycerophosphate and protease inhibitors (Complete Mini EDTA-free, Roche Applied Science, Indianapolis, IN). Lysates were sonicated, boiled and resolved on 4--12% NuPage Bis-Tris acrylamide gels (Invitrogen, Carlsbad, CA), then transferred to nitrocellulose. Membranes were blocked in 10% non-fat dried milk and probed overnight with phospho-ERK1/2, (Cell Signaling, Boston, MA), phospho-p38 or phospho-IκB antibodies (Santa Cruz Biotechnology Inc, Santa Cruz, CA). After incubation with peroxidase conjugates the blots were detected on a CCD-camera based detection system (GBox, Syngene USA, Frederick, MD) with enhanced chemiluminescent substrate. To normalize signals, membranes were stripped in 62.5 mM Tris, 2% SDS, 100 mM ß-mercaptoethanol at 60°C for 30 min, blocked and re-probed with antibodies against ERK1/2, p38 and IκB. The signals were quantitated using Genetools analysis software (Syngene USA, Frederick, MD).

Pharmacological Modulation of HMGB1-induced TNFα Production *in vivo* {#s2h}
---------------------------------------------------------------------

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Texas Medical Branch, Galveston (Permit Number: 1110054). The procedures were performed humanely with minimal suffering. 6--7 week-old Balb/c male mice (The Jackson Laboratory) were pretreated subcutaneously with 20 mg/kg prednisolone, 10 mg/kg salbutamol, the combination of prednisolone and salbutamol (doses as above), or the glucocorticoid receptor blocker mifepristone (30 mg/kg) or the β-receptor antagonist propranolol (10 mg/kg) or vehicle for 3 hours. Mice were injected intraperitoneally (i.p.) with 0.5 mg/mouse HMGB1 and animals were sacrificed 8 hours later. Serum levels of TNFα were measured by ELISA (as above).

### Statistical analysis {#s2h1}

Data are shown as means ± SEM. One-way ANOVA was applied for statistical analysis and for the determination of significance, the Tukey's post-hoc test was used. A p value of \<0.05 was considered statistically significant. All statistical calculations were performed using Graphpad Prism 4 analysis software. Experiments were performed at least 3 times on different days.

Results {#s3}
=======

HMGB1 Induces Inflammatory Mediator Production and Cytotoxicity in RAW 264.7 Macrophages {#s3a}
----------------------------------------------------------------------------------------

HMGB1 (1--10 µg/ml) induced concentration-dependent tumor necrosis factor α (TNFα) secretion by RAW 264.7 cells, an effect, which was potentiated by IFN-γ ([Fig. 1A](#pone-0065994-g001){ref-type="fig"}). HMGB1 also reduced cell viability ([Fig. 1B](#pone-0065994-g001){ref-type="fig"}); this cytotoxic response became more pronounced at later time points (48 h, 72 h) ([Fig. 2](#pone-0065994-g002){ref-type="fig"}) and was associated with a suppression of mitochondrial function ([Fig. 3](#pone-0065994-g003){ref-type="fig"}) and caspase activation ([Fig. 4](#pone-0065994-g004){ref-type="fig"}). In addition to TNFα, HMGB1 also upregulated multiple pro-inflammatory cytokine (IL1a, IL1b, IL6, TNFβ) and chemokine (Ccl2, MCP-1, Cxcl10) genes, as well as the anti-inflammatory cytokine IL10 ([Fig. 1C](#pone-0065994-g001){ref-type="fig"}). The HMGB1-mediated responses were also associated with an upregulation of nuclear factor κB (NF-κB) ([Fig. 1C](#pone-0065994-g001){ref-type="fig"}). Moreover, HMGB1 induced a down-regulation of TLR4 and MD2 and upregulation of TLR2, TLR9 and TLR adaptor molecule 1 (Ticam1) ([Fig. 1C](#pone-0065994-g001){ref-type="fig"}). Thus, the form of HMGB1 used for the screen exhibited the expected cytokine like properties of C23-C45 disulfide C106 thiol HMGB1.

![HMGB1 induces an inflammatory response in RAW 264.7 macrophages.\
**A--B:** RAW 264.7 cells were treated with the indicated amount of HMGB1 and IFN-γ for 18 hours and the TNFα secretion was measured in the supernatant. The viability of the cells was measured by the MTT assay. (\*p\<0.05 compared to vehicle treated cells, ^\#^p\<0.05 IFN-γ treated group compared to the respective HMGB1-treated group) **C:** RAW 264.7 cells were treated with HMGB1 (5 µg/ml) for 1.5 hours and the expression of TLR-associated genes was analyzed with TLR signaling pathways array. The gene symbols and the average fold-expression values are shown compared to vehicle-treated cells in the color-scale, according to the their relative expression. (\*p\<0.05 compared to vehicle-treated cells.).](pone.0065994.g001){#pone-0065994-g001}

![Concentration- and time-dependence of the HMGB1-induced inflammatory response and reduction in cell viability in RAW 264.7 macrophages.\
RAW 264.7 cells were treated with the indicated amount of HMGB1 for 24, 48 or 72 hours. **A:** Cell viability was measured with the MTT assay and **B:** TNFα secretion was measured in the supernatant.](pone.0065994.g002){#pone-0065994-g002}

![Time-dependence of the HMGB1-induced suppression of cellular bioenergetics in RAW 264.7 macrophages.\
RAW 264.7 cells were exposed to HMGB1 (5 µg/ml) for 24, 48 or 72 hours. Cellular bioenergetic parameters were measured with Seahorse extracellular fluid analysis. **A:** Time-dependent decrease in basal cellular respiration (Oxygen Consumption Rate, OCR). (\*\*p\<0.01 compared to vehicle treated cells) **B:** Time-dependent decrease in maximal cellular respiration. (\*p\<0.05 and \*\*p\<0.01 compared to vehicle treated cells). **C:** Representative tracing comparing cellular respiration (Oxygen Consumption Rate) in response to sequential administration of pharmacological modulators of cell metabolism in vehicle-treated cells or cells treated with HMGB1 for 72 hours. Basal Respiration, Calculated ATP Turnover, Proton Leak and Maximal Respiration areas are indicated and demonstrate a marked suppression of cellular bioenergetic parameters.](pone.0065994.g003){#pone-0065994-g003}

![HMGB1 induces time-dependent caspase activation in RAW 264.7 macrophages.\
RAW 264.7 cells were exposed to HMGB1 (5 µg/ml) for 24, 48 or 72 hours. Activated Caspase-3 was detected in cell extracts by Western blotting. Tubulin was used for loading control. The graph shows relative Caspase-3 activation values, normalized to tubulin. (\*\*p\<0.01 shows significant caspase activation compared to vehicle-treated cells).](pone.0065994.g004){#pone-0065994-g004}

Identification of Inhibitors of HMGB1-induced TNFα Production by Cell-based Screening {#s3b}
-------------------------------------------------------------------------------------

Cell-based screening of a focused library of over 5,000 clinical drugs, natural products and pharmacologically active compounds identified ∼2% of the compounds, which suppressed TNFα production, without adversely affecting cell viability ([Table 1](#pone-0065994-t001){ref-type="table"}; [Fig. 5](#pone-0065994-g005){ref-type="fig"}). Conversely, a limited number of compounds induced a significant enhancement of HMGB1-mediated TNFα response ([Table 2](#pone-0065994-t002){ref-type="table"}). A full list of the primary screen data is deposited in [Table S2](#pone.0065994.s002){ref-type="supplementary-material"}.

![Screening for compounds that reduce the HMGB1-induced pro-inflammatory response.\
**A:** Timeline of the cell-based screening: RAW 264.7 cells were pre-treated with test compounds and exposed to HMGB1 for 18 hours. TNFα production was measured from the supernatant and the viability of the cells was measured by the MTT assay. **B:** Dot graph showing the individual TNFα/viability results of the tested 5,646 compounds. TNFα responses are shown as % values of the HMGB1-induced TNFα production. Values lower than MEAN-2SD are shown in red (viability) and green (TNFα response) boxes to denote "toxic" and "Hit" compounds. **C--D:** Distribution of viability (C) and TNFα response (D) data with superimposed Gaussian distribution curves fitted to the data points.](pone.0065994.g005){#pone-0065994-g005}

10.1371/journal.pone.0065994.t001

###### List of hit compounds identified in the primary screen.

![](pone.0065994.t001){#pone-0065994-t001-1}

  Name                                   Library                                Biological activity                        TNFα production (% of HMGB1 stimulation)   viability (%)
  ----------------------------- ------------------------- --------------------------------------------------------------- ------------------------------------------ ---------------
  piperlongumine                    Natural Products                      anti-inflammatory, antioxidant                                      0                            94
  indapamide                            ENZO FDA                               sulphonamide diuretic                                          0                            92
  parthenolide                          Prestwick                     MAP kinase inhibitor anti-inflammatory                                  2                            92
  stattic                                 LOPAC                             STAT3 activation inhibitor                                        14                           125
  parthenolide                            LOPAC                       MAP kinase inhibitor anti-inflammatory                                  20                           104
  U0126                                   LOPAC                   inhibitor of MEK1 and MEK2 (MAP kinase kinase)                              20                           92
  rubescensin A                    Microsource Killer                      antibacterial, antineoplastic                                      21                           93
  2′,4′-dihydroxyflavone            Natural Products                                  flavone                                                 21                           83
  ethylnorepinephrin               Microsource US Drug                  adrenergic agonist, bronchodilator                                    22                           112
  parthenolide                      Natural Products                  MAP kinase inhibitor anti-inflammatory                                  23                           102
  dexamethasone                         Prestwick                             glucocorticoid steroid                                          23                           100
  betamethasone                         Prestwick                             glucocorticoid steroid                                          24                           90
  metaproterenol                        Prestwick                     beta-adrenergic agonist, bronchodilator                                 26                           87
  budesonide                            Prestwick                             glucocorticoid steroid                                          27                           96
  dexamethasone                    Microsource US Drug                        glucocorticoid steroid                                          29                           107
  hydrocortisone base                   Prestwick                             glucocorticoid steroid                                          29                           115
  tolnaftate                            Prestwick                                   antifungal                                                29                           90
  fludrocortisone                       Prestwick                        mineralocorticoid, glucocorticoid                                    30                           98
  dexamethasone                    Microsource US Drug                        glucocorticoid steroid                                          30                           106
  fenoterol hydrobromide                Prestwick                    beta-adrenergic agonist, bronchodilatator                                31                           100
  tyloxapol                        Microsource US Drug                     polymeric nonionic detergent                                       31                           92
  triamcinolone                         Prestwick                             glucocorticoid steroid                                          31                           92
  6-alpha-methylprednisolone            Prestwick                             glucocorticoid steroid                                          31                           110
  flumethasone                     Microsource US Drug                        glucocorticoid steroid                                          31                           109
  ST057244                          Natural Products                                                                                          32                           85
  isoalantolactone                  Natural Products                           sesquiterpene lactone                                          32                           101
  ritodrine                             Prestwick                      beta~2~ adrenergic agonist, tocolytic                                  32                           98
  imipenem                              Prestwick                                   antibiotic                                                32                           101
  clenbuterol                           Prestwick                    beta-adrenergic agonist, bronchodilatator                                32                           98
  prenylamine                           Prestwick                       Ca^++^ channel blocker, vasodilator                                   33                           87
  hydrocortisone                    Natural Products                          glucocorticoid steroid                                          33                           113
  lidocaine                             Prestwick                     Na^+^ channel blocker, local anesthetic                                 33                           91
  prednisolone                          Prestwick                             glucocorticoid steroid                                          33                           107
  flurandrenolide                  Microsource US Drug                        glucocorticoid steroid                                          33                           116
  prednisolone                     Microsource US Drug                        glucocorticoid steroid                                          34                           110
  bethamethasone                   Microsource US Drug                        glucocorticoid steroid                                          34                           129
  fluticasone                           Prestwick                             glucocorticoid steroid                                          34                           78
  clenbuterol                     Microsource Intl Drug             beta2-adrenergic agonist, bronchodilatator                                35                           111
  ibudilast                               LOPAC                           phosphodiesterase IV inhibitor                                      35                           101
  Bay 11-7085                             LOPAC                  IκB phosphorylation inhibitor, inhibitor of NF-κB                            35                           94
  fluocinolone                     Microsource US Drug                        glucocorticoid steroid                                          35                           115
  tulobuterol                     Microsource Intl Drug              beta-adrenergic agonist, bronchodilatator                                35                           111
  clobetasol propionate                 Prestwick                             glucocorticoid steroid                                          36                           146
  flurandrenolide                       Prestwick                             glucocorticoid steroid                                          36                           107
  prednisolone                      Natural Products                          glucocorticoid steroid                                          36                           106
  flunisolide                      Microsource US Drug                        glucocorticoid steroid                                          36                           109
  dexamethasone                     Natural Products                          glucocorticoid steroid                                          37                           104
  flumethasone                          Prestwick                             glucocorticoid steroid                                          37                           133
  albuterol                        Microsource US Drug               beta-adrenergic agonist, bronchodilatator                                37                           100
  hydrocortisone                    Natural Products                          glucocorticoid steroid                                          37                           109
  flumethasone                     Microsource US Drug                        glucocorticoid steroid                                          38                           117
  nordihydroguaiaretic acid         Natural Products                   from creosote bush, Larrea divaricata                                  38                           92
  2,6-dimethoxyquinone             Microsource Killer                         antibacterial, mutagen                                          38                           82
  dichlorisone                    Microsource Int Drug                        glucocorticoid steroid                                          38                           107
  salbutamol                            Prestwick                    beta-adrenergic agonist, bronchodilatator                                38                           102
  bethamethasone                   Microsource US Drug                        glucocorticoid steroid                                          39                           114
  hydrocortisone                          LOPAC                               glucocorticoid steroid                                          39                           110
  triamcinolone                         ENZO FDA                              glucocorticoid steroid                                          39                           109
  desoxymetasone                   Microsource US Drug                        glucocorticoid steroid                                          39                           126
  mometasone                            Prestwick                             glucocorticoid steroid                                          39                           124
  Bay 11-7082                             LOPAC                  IκB phosphorylation inhibitor, inhibitor of NF-κB                            39                           95
  prednisolone                     Microsource US Drug                        glucocorticoid steroid                                          39                           110
  fluorometholone                       Prestwick                             glucocorticoid steroid                                          39                           104
  3,7,4′-trihydroxyflavone          Natural Products                                  flavone                                                 39                           81
  budesonide                       Microsource US Drug                        glucocorticoid steroid                                          39                           110
  halomethasone                  NIH Clinical Collection                      glucocorticoid steroid                                          39                           106
  fluorometholone                  Microsource US Drug                        glucocorticoid steroid                                          40                           114
  triamcinolone                    Microsource US Drug                        glucocorticoid steroid                                          40                           115
  ST009819                          Natural Products                        levoglucosenone derivative                                        40                           101
  prednisolone                          ENZO FDA                              glucocorticoid steroid                                          40                           124
  hydrocortisone                   Microsource US Drug                        glucocorticoid steroid                                          40                           115
  fluticasone                    NIH Clinical Collection                      glucocorticoid steroid                                          40                           93
  rimexolone                            Prestwick                             glucocorticoid steroid                                          40                           96
  isoproterenol                         Prestwick                      adrenergic agonist, bronchodilatator                                   40                           109
  methylprednisolone               Microsource US Drug                        glucocorticoid steroid                                          41                           115
  methylprednisolone                    ENZO FDA                              glucocorticoid steroid                                          41                           95
  metaproterenol                   Microsource US Drug                 adrenergic agonist, bronchodilatator                                   41                           104
  karanjin                          Natural Products                     from Pongamia glabra, Leguminosae                                    41                           100
  salmeterol                            ENZO FDA                    beta~2~-adrenergic agonist, bronchodilator                                41                           111
  betamethasone                         ENZO FDA                              glucocorticoid steroid                                          41                           101
  clobetasol                       Microsource US Drug                        glucocorticoid steroid                                          41                           107
  budesonide                              LOPAC                               glucocorticoid steroid                                          41                           115
  isotretinon                      Microsource US Drug                       antiacne, antineoplastic                                         41                           115
  benzyl isothiocyanate            Microsource Killer                antineoplastic, antibacterial, antifungal                                41                           89
  quinacrine                       Microsource Killer             anthelmintic, antimalarial, intercalating agent                             42                           77
  flunisolide                           Prestwick                             glucocorticoid steroid                                          42                           113
  ellipticine                             LOPAC            cytochrome P~450~ (CYP1A1) and DNA topoisomerase II inhibitor                      42                           95
  terbutaline hemisulfate               Prestwick                   beta~2~-adrenergic agonist, bronchodilator                                42                           96
  alclometazone                    Microsource US Drug                        glucocorticoid steroid                                          42                           112
  methylprednisolone               Microsource US Drug                        glucocorticoid steroid                                          42                           113
  2′,3′-dihydroxyflavone            Natural Products                                  flavone                                                 42                           88
  (+)-dehydroabietylamine           Natural Products                 ingredient of rosin amine, from Rosin Gum                                42                           90
  triamcinolone                    Microsource US Drug                        glucocorticoid steroid                                          43                           113
  betamethasone                    Microsource US Drug                        glucocorticoid steroid                                          43                           112
  isoflupredone                         Prestwick                             glucocorticoid steroid                                          43                           99
  alclometasone                         Prestwick                             glucocorticoid steroid                                          43                           147
  p-aminobenzoate                  Microsource US Drug                             vitamin B~x~                                               43                           118
  dexamethasone                         ENZO FDA                              glucocorticoid steroid                                          43                           113
  indinavir                      NIH Clinical Collection                      HIV protease inhibitor                                          43                           96
  ethacrynic acid                  Microsource US Drug                               diuretic                                                 43                           96
  beclomethasone                   Microsource US Drug                        glucocorticoid steroid                                          43                           112
  amcinonide                       Microsource US Drug                        glucocorticoid steroid                                          43                           109
  MNS                                     LOPAC                            Src and Syk kinase inhibitor                                       43                           93
  sulfasalazine                         Prestwick                 prostaglandin 15-hydroxydehydrogenase inhibitor                             44                           97
  betamethasone                    Microsource US Drug                        glucocorticoid steroid                                          44                           119
  fludrocortisone                  Microsource US Drug                   mineralocorticoid, glucocorticoid                                    44                           115
  5,3′-dihydroxyflavone             Natural Products                            flavone derivative                                            44                           99
  methyl cholate                    Natural Products                                                                                          44                           97
  desonide                         Microsource US Drug                        glucocorticoid steroid                                          44                           115
  tolazoline                            Prestwick                    alpha adrenergic antagonist, vasodilator                                 44                           87
  vincristine                           ENZO FDA               antineoplastic, microtubular polymerization inhibitor                          44                           94
  ethacrynic acid                       Prestwick                                    diuretic                                                 45                           98
  levonordefrin                         Prestwick                       adrenergic agonist, vasoconstrictor                                   45                           116
  isofluprednone                   Microsource US Drug                        glucocorticoid steroid                                          45                           123
  4′-hydroxy-6-methoxyflavone       Natural Products                                  flavone                                                 45                           80
  fluocinolone                          ENZO FDA                              glucocorticoid steroid                                          45                           106
  alprostadil                           Prestwick                   vasodilator, prostaglandin receptor agonist                               45                           82
  maprotiline                           Prestwick                 antidepressant, noradrenaline uptake inhibitor                              45                           99
  dobutamine                            Prestwick                   beta~1~-adrenergic agonist, bronchodilator                                45                           92
  betamethasone                    Microsource US Drug                        glucocorticoid steroid                                          45                           122
  bromperidol                           Prestwick                       antipsychotic, dopamine antagonist                                    45                           85

Non-toxic compounds that reduced the HMGB1-induced TNFα production by 2 standard deviation values are listed in order of potency, according to their inhibitory potency for TNFα secretion. The source library of the compounds, their known biological activity and the respective viability values are shown. Viability was measured by the MTT assay. (Abbreviations: MAP kinase: Mitogen-activated protein kinase, U0126∶1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene, MEK: mitogen-activated protein kinase kinase, STAT3: Signal transducer and activator of transcription 3, ST057244∶1-\[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl\]piperidin-2-one, Bay 11-7085: (2*E*)-3-\[\[4-(1,1-dimethylethyl)pheny?l\]sulfonyl\]-2-propenenitrile, Bay 11-7082∶3- \[(4- methylphenyl)sulfonyl\]- (2E)- propenenitrile, ST009819: (2R,3R,13R,14R)-3-(phenylcarbonyl)-17,19-dioxa-4-azapentacyclo\[14.2.1.0\<2,14\>. 0\<4,13\>.0\<7,12\>\]nonadeca-5,7(12),8,10-tetraen-15-one, MNS: 3,4-methylenedioxy-β-nitrostyrene, IkB: inhibitor of nuclear factor κB kinase, NF-κB: nuclear factor κB, HIV: human immunodeficiency virus, Src: sarcoma tyrosine kinase, Syk: Spleen tyrosine kinase).

10.1371/journal.pone.0065994.t002

###### Compounds that enhance the HMGB1-induced TNFα production of RAW264.7 cells.

![](pone.0065994.t002){#pone-0065994-t002-2}

  Name                               Library                                Biological activity                         TNFα production (% of HMGB1 stimulation)   viability (%)
  --------------------------- ---------------------- ----------------------------------------------------------------- ------------------------------------------ ---------------
  beta-escin                        Prestwick         an increaser of calcium permeability, venous insufficiency drug                     351                           101
  thapsigargin                        LOPAC                 sarco-endoplasmic reticulum Ca^2+^-ATPase inhibitor                           336                           13
  niclosamide                   Microsource Killer           anthelmintic, uncouples oxidative phosphorylation                            335                           67
  wortmannin                          LOPAC                       phosphatidylinositol 3-kinase inhibitor                                 330                           93
  calcimycin                          LOPAC                                  Ca^2+^ ionophore                                             327                            1
  gossypol                            LOPAC               proapoptotic, binds calmodulin, PKC inhibitor, anti-HIV                         321                           88
  niclosamide                         LOPAC                  anthelmintic, uncouples oxidative phosphorylation                            302                           39
  tyrphostin A9                       LOPAC                       PDGF tyrosine kinase receptor inhibitor                                 289                           51
  rottlerin                           LOPAC                               mitochondrial uncoupler                                         261                           99
  5-azacytidine                     Prestwick                    antineoplastic, pyrimidine antimetabolite                                260                           57
  5-azacytidine                Microsource US Drug               antineoplastic, pyrimidine antimetabolite                                257                           84
  vinblastine                  Microsource US Drug                    antineoplastic, spindle poison                                      256                           86
  imiquimod                         Prestwick               immunomodulator, activator of Toll-Like Receptor 7                            243                           84
  5-azacytidine                 Microsource Killer               antineoplastic, pyrimidine antimetabolite                                241                           59
  niclosamide                       Prestwick                anthelmintic, uncouples oxidative phosphorylation                            239                           58
  vincristine                  Microsource US Drug                  antineoplastic, microtubular agent                                    211                           87
  ivermectin                         ENZO FDA                                  antiparasitic                                              206                           86
  gossypol                      Microsource Killer        proapoptotic, binds calmodulin, PKC inhibitor, anti-HIV                         204                           112
  rottlerin                      Natural Products                         mitochondrial uncoupler                                         196                           77
  pararosaniline               Microsource US Drug                    anthelmintic, antischistosomal                                      195                           89
  podophyllotoxin                Natural Products                   antineoplastic, microtubular agent                                    188                           78
  colchicine                   Microsource US Drug                  antineoplastic, microtubular agent                                    187                           79
  cantharidic acid                    LOPAC                       protein phosphatase 1 and 2A inhibitor                                  177                           37
  podophyllotoxin              Microsource US Drug                  antineoplastic, microtubular agent                                    171                           84
  fluvastatin                        ENZO FDA                       statin, HMG-CoA reductase inhibitor                                   168                           127
  tyrphostin AG 879                   LOPAC                tyrosine kinase inhibitor with potent effects on TrkA                          165                           65
  itavastatin                  NIH Clin. Collection                 statin, HMG-CoA reductase inhibitor                                   163                           105
  simvastatin                       Prestwick                       statin, HMG-CoA reductase inhibitor                                   162                           106
  fluvastatin                       Prestwick                       statin, HMG-CoA reductase inhibitor                                   162                           111
  8-azaguanine                      Prestwick                      antineoplastic, purine antimetabolite                                  159                           74
  methiazole                        Prestwick                                  antiparasitic                                              159                           77
  N-oleoyldopamine                    LOPAC               endogenous vanilloid, weak cannabinoid receptor ligand                          158                           24
  oxaliplatin                        ENZO FDA                         antineoplastic DNA crosslinker                                      157                           94
  hexachlorophene               Microsource Killer      disinfectant, topical anti-infective, anti-bacterial agent                        156                           99
  cerivastatin                 NIH Clin. Collection                 statin, HMG-CoA reductase inhibitor                                   156                           100
  colchicine                    Microsource Killer                  antineoplastic, microtubular agent                                    155                           77
  parbendazole                      Prestwick                        anthelmintic, microtubular agent                                     155                           80
  5-azacytidine                       LOPAC                      antineoplastic, pyrimidine antimetabolite                                155                           61
  mevastatin                          LOPAC                         statin, HMG-CoA reductase inhibitor                                   153                           110
  tridihexethyl                     Prestwick                          anticholinergic antispasmodic                                      153                           96
  cerivastatin                       ENZO FDA                       statin, HMG-CoA reductase inhibitor                                   153                           121
  nordihydroguaiaretic acid           LOPAC                         antioxidant from Larrea divaricata                                    153                           113
  norcantharidin                      LOPAC              inhibitor of the serine/threonine protein phosphatase 2A                         151                           108
  tannic acid                   Microsource Killer                  nonspecific enzyme/receptor blocker                                   150                           99

Compounds augmenting the HMGB1-induced TNFα production by 2 standard deviation values are listed are listed in order of potency, according to their enhancing effect on TNFαα secretion. The source library of the compounds, their known biological activity and the respective viability values are shown. Viability was measured by the MTT assay. (Abbreviations: PKC: protein kinase C, HIV: human immunodeficiency virus, PDGF: platelet-derived growth factor, HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme A, TrkA: TRK1-transforming tyrosine kinase protein).

More than 50% of the hit compounds that inhibited TNFα production were glucocorticoids ([Fig. 5](#pone-0065994-g005){ref-type="fig"}; [Table 1](#pone-0065994-t001){ref-type="table"}). Beta-adrenergic agonists represented the second-most common class. The activity of the hit compounds was next confirmed at 3 and 10 µM. Since glucocorticoids and beta agonists showed a clear class action, only a subset of these compounds was retested. Apart from glucocorticoids and beta agonists, the highest inhibitory activity was detected for the NF-κB inhibitors Bay 11-7085 and parthenolide, and the antioxidant piperlongumine. Increasing the concentration of the compounds to 10 µM did not produce more pronounced inhibitory responses, but approximately 15% of the hit compounds became slightly cytotoxic at this concentration ([Table 3](#pone-0065994-t003){ref-type="table"}).

10.1371/journal.pone.0065994.t003

###### List of confirmed hit compounds.

![](pone.0065994.t003){#pone-0065994-t003-3}

  Compound                  Biological activity       Source Library   Primary screen   Hit confirmation               
  --------------------- ---------------------------- ---------------- ---------------- ------------------ ------------ --------
  Parthenolide                NF-κB inhibitor           Prestwick            2                 92             21±2      0±0\*
  Bay 11-7085                 NF-κB inhibitor             LOPAC              35                94             25±1      2±1\*
  Ethylnorepinephrine     beta adrenergic agonist        US Drug             22               112             31±0       26±1
  Halomethasone                glucocorticoid          NIH Clinical          39               106             36±2       34±1
  Salbutamol              beta adrenergic agonist       Prestwick            38               102             37±1       37±6
  Dexamethasone                glucocorticoid           Prestwick            23               100             39±3       30±2
  Budesonide                   glucocorticoid             LOPAC              41               115             41±3       38±1
  Indinavir                HIV protease inhibitor      NIH Clinical          43                96             42±3       42±3
  Ethacrynic acid                 diuretic               US Drug             43                96             44±0      3±1\*
  Fluticasone                  glucocorticoid          NIH Clinical          40                93             44±4      43±1\*
  Hydrocortisone               glucocorticoid             LOPAC              39               110             45±1       45±3
  Metaproterenol          beta adrenergic agonist       Prestwick            26                87             48±3       50±4
  Fenoterol               beta adrenergic agonist       Prestwick            31               100             51±1       56±1
  Ritodrine              beta~2~ adrenergic agonist     Prestwick            32                98             51±4       48±6
  Terbutaline            beta~2~ adrenergic agonist     Prestwick            42                96             51±2       50±3
  Isoflupredone                glucocorticoid           Prestwick            43                99             52±5       51±2
  Clenbuterol             beta adrenergic agonist       Prestwick            32                98             52±4       44±5
  MNS                     Src/Syk kinase inhibitor        LOPAC              43                93             54±2      9±1\*
  Ethacrynic acid                 diuretic              Prestwick            45                98             59±5      39±2\*
  Levonordefrin              adrenergic agonist         Prestwick            45               116             64±1       56±8
  PABA potassium salt            vitamin Bx              US Drug             43               118             65±1       59±1
  Isoproterenol              adrenergic agonist         Prestwick            40               109             67±2       58±5
  Prenylamine             calcium channel blocker       Prestwick            33                87             69±4       59±4
  Tyloxapol                      surfactant              US Drug             31                92             78±0       57±2
  Isotretinoin                    retinoid               US Drug             41               115             79±2       60±5
  Piperlongumine           antioxidant in peppers       Nat. Prod.           0                 94             80±1      39±3\*
  Lidocaine                   local anesthetic          Prestwick            33                91          not tested  

Hit compounds of the primary screen were retested in replicates at 3 and 10 µM against HMGB1 and LPS and compounds are shown that decreased the HMGB**-**induced TNFα production by at least 40% in the hit confirmation experiments. (The majority of the glucocorticoids were not retested during the hit confirmation studies, since all glucocorticoids showed similar activity, confirming their class action.) TNFα production and viability values are shown for the primary screen and the TNFα production is shown for the hit confirmation experiments (Mean±SD). Compounds that reduced cell viability by at least 25% are labeled with an asterisk. (Abbreviations: Bay 11-7085: (2*E*)-3-\[\[4-(1,1-dimethylethyl)phenyl\]sulfonyl\]-2-propenenitrile, MNS: 3,4-methylenedioxy-β-nitrostyrene, PABA potassium salt: para-aminobenzoic acid potassium salt, NF-κB: nuclear factor κB, HIV: human immunodeficiency virus, Src: sarcoma tyrosine kinase, Syk: Spleen tyrosine kinase).

Identification of Pharmacological Potentiators of Glucocorticoids by Cell-based Screening {#s3c}
-----------------------------------------------------------------------------------------

We hypothesized that synergistic drug combinations may be more effective than single agents in controlling HMGB1-induced inflammatory responses. To identify compounds that potentiate the effect of glucocorticoids, a follow-up screen of the NIH Clinical Collection compound library was conducted in the presence of dexamethasone (3 µM). The screen identified beta2 agonists (salbutamol, salmeterol), the phosphodiesterase (PDE) inhibitor rolipram and as prostaglandin E1 as synergistic enhancers of the glucocorticoid\'s effect ([Fig. 6](#pone-0065994-g006){ref-type="fig"}, [Table 4](#pone-0065994-t004){ref-type="table"}). In addition, the dopamine receptor antagonist SCH 23390 (*R*)-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine HCl), the structurally related benzodiazepine lorazepam, the antioxidant ebselen and the δ1 opioid receptor agonist SB 205607 decreased TNFα production in the presence of the glucocorticoid. As expected, the glucocorticoid receptor antagonist mifepristone attenuated the effect of dexamethasone ([Table 4](#pone-0065994-t004){ref-type="table"}). A few drugs (e.g. cerivastatin, vindesine, vinorelbine) increased TNFα production in the presence dexamethasone ([Table 4](#pone-0065994-t004){ref-type="table"}); this effect was related to the fact that, according to the results of the primary screen, these compounds, on their own, increase HMGB1-induced TNFα secretion ([Table 1](#pone-0065994-t001){ref-type="table"}).

![Combined screening to identify pharmacological potentiators of dexamethasone-mediated inhibition of the HMGB1-induced pro-inflammatory response.\
RAW 264.7 cells were pre-treated with dexamethasone (3 µM) in combination with test compounds and exposed to HMGB1 for 18 hours. TNFα production was measured from the supernatant and the viability of the cells was measured by the MTT assay. **A:** TNFα responses measured in the combination screen are plotted versus the TNFα production values measured in the single compound screen. TNFα production values higher than MEAN+2SD are shown in red ("steroid inhibitors") and values lower than MEAN+2SD in green boxes ("potentiators of steroids) for the combination screen. Red dots denote the toxic compounds, green the steroid potentiators and purple those that increase the TNFα production. Compounds that inhibited the HMGB-induced TNFα production in the single compound screen, but failed to potentiate the action of steroids are shown in yellow. **B:** TNFα responses relative to the activity of dexamethasone are plotted versus the viability values. Red and green boxes indicate the upper and lower 2 SD limits.](pone.0065994.g006){#pone-0065994-g006}

10.1371/journal.pone.0065994.t004

###### Compounds of interest identified by screening of the NIH Library in the presence of 3 µM dexamethasone on HMGB1-induced TNFα production.

![](pone.0065994.t004){#pone-0065994-t004-4}

  Compound                                                                                                    Biological activity           Single compound screen   Steroid combination screen       
  --------------------------------------------------------------------------------------------------- ------------------------------------ ------------------------ ---------------------------- ---- -----
  **Steroid action enhancers (potentiators)**                                                                                                                                                         
  salmeterol                                                                                               beta~2~ adrenergic agonist                 50                        102               21   111
  rolipram                                                                                                phosphodiesterase inhibitor                 60                         86               23   109
  prostaglandin E1                                                                                               prostaglandin                        55                         97               23   109
  salbutamol sulfate                                                                                       beta~2~ adrenergic agonist                 51                         91               25   110
  lorazepam                                                                                                      benzodiazepine                       50                         95               27   108
  SB 205607                                                                                               δ~1~ opioid receptor agonist                53                        102               29   110
  R(+)-SCH-23390 HCl                                                                                   D~1~ dopamine receptor antagonist              73                         96               30   110
  ebselen                                                                                                anti-inflammatory antioxidant                85                        103               34   117
  **Hit compounds in single-compound screen that do not enhance steroid action (non-potentiators)**                                                                                                   
  fluticasone propionate                                                                                     glucocorticoid steroid                   40                         93               43   108
  halometasone monohydrate                                                                                   glucocorticoid steroid                   39                        106               44   107
  tadalafil                                                                                                      PDE5 inhibitor                       49                        107               44   108
  tropisetron HCl                                                                                         serotonin 5-HT~3~ antagonist                46                         99               44   110
  indinavir sulfate                                                                                          HIV protease inhibitor                   43                         96               48   105
  beclomethasone                                                                                             glucocorticoid steroid                   54                        108               49   106
  zaleplon                                                                                                GABA A α~1~ agonist hypnotic                52                        101               50   109
  desoximetasone                                                                                             glucocorticoid steroid                   52                        108               50   111
  pergolide mesylate salt                                                                                  dopamine receptor agonist                  60                         99               54   110
  loteprednol etabonate                                                                                      glucocorticoid steroid                   59                        104               62   108
  **Compounds that counteract dexamethasone (steroid inhibitors)**                                                                                                                                    
  cerivastatin Na                                                                                                    statin                         \>150                       100               83   126
  rutin                                                                                                  platelet aggregation inhibitor              102                         97               69   112
  ritonavir                                                                                                  HIV protease inhibitor                  112                         98               73   113
  vinorelbine bitartarate                                                                                        antineoplastic                      112                         78               78   106
  vindesine sulfate                                                                                            mitotic inhibitor                     120                         69               96   84
  mifepristone                                                                                         glucocorticoid receptor antagonist            101                        101               92   115
  **Toxic compounds**                                                                                                                                                                                 
  dactinomycin                                                                                                    antibiotics                         1                          1                0     2
  triptolide                                                                                                    NF-κB inhibitor                       0                          2                0     1
  homoharringtonine                                                                                         60-S ribosome inhibitor                   0                          1                1     1
  idarubicin HCl                                                                                               anti-leukemic drug                     6                          2                9     2
  epirubicin HCl                                                                                               anthracycline drug                     12                         2                18   15
  doxorubicin HCl                                                                                              anthracycline drug                     45                         4                31   32
  topotecan HCl                                                                                             topoisomerase inhibitor                   94                         49               45   94
  indarubicin                                                                                                    antineoplastic                      100                         72               54   94
  diphenylcyclopropenone                                                                                 local immune response inducer               114                         71               56   100
  artesunate                                                                                                 anti-malaria compound                   121                         74               75   78
  vincristine sulfate                                                                                          mitotic inhibitor                     130                         72               90   80

Compounds of interest are shown with their respective TNFα response and viability values attained in the single compound and combined screens. Drugs that reduced the TNFα response compared to the action of dexamethasone are classified as potentiators. Drugs that decreased the TNFα response by themselves, but showed negligible increase in their activity in combination with dexamethasone are listed as non-potentiators. Compounds that resulted in higher TNFα secretion (\>MEAN+2SD) are listed as steroid inhibitors. Compounds that reduced the viability by more than 2 SD (\<75% viability) are listed as toxic compounds.

Glucocorticoid/beta-adrenergic Agonist Synergy: Mechanism of Action {#s3d}
-------------------------------------------------------------------

Using prednisolone (a prototypical glucocorticoid) and salbutamol (a prototypical beta 2 adrenergic agonist), follow-up experiments were designed to further characterize the pharmacological properties and underlying mechanisms of the glucocorticoid/beta-adrenergic synergy. Both prednisolone and salbutamol, on their own, decreased the HMGB1-induced TNFα production in the low nanomolar concentration range: they reached their maximum effect at around 100--300 nM, exhibiting a 50% inhibition of TNFα production ([Fig. 7](#pone-0065994-g007){ref-type="fig"}). Salbutamol (1 µM), in combination with prednisolone, significantly reduced TNFα production already at 10 nM (compared to salbutamol alone); at 100 nM prednisolone the combination reached its full potential (approximately 70% inhibition). Likewise, the combination of prednisolone (1 µM) with 30 nM salbutamol significantly reduced the HMGB1-induced TNFα response (compared to prednisolone alone) and with 300 nM salbutamol the combination reached its full potential (approximately 70% inhibition) ([Fig. 7](#pone-0065994-g007){ref-type="fig"}).

![Prednisolone and salbutamol synergistically suppress HMGB1-induced TNFα secretion.\
RAW 264.7 cells were pretreated with prednisolone and salbutamol at the indicated concentrations and exposed to HMGB1 (5 µg/ml) for 18 hours. TNFα secretion (**A, B**) and LDH release (**E, F**) were measured in the supernatant. Cell viability (**C, D**) was measured by the MTT assay. (^§^p\<0.05 HMGB1-treated group compared to vehicle treated control, \*p\<0.05 compared to HMGB1 group, ^\#^p\<0.05 compared to the respective first compound treatment).](pone.0065994.g007){#pone-0065994-g007}

HMGB1-induced TNFαα secretion was associated with a rapid-onset and marked increase in TNFα mRNA ([Fig. 8](#pone-0065994-g008){ref-type="fig"}). Prednisolone and salbutamol each decreased the TNFα mRNA level by 50%; combination of the two compounds synergistically inhibited the transcription of TNFα mRNA ([Fig. 8](#pone-0065994-g008){ref-type="fig"}). We next tested whether the early inhibition of TNFα production involves upstream signaling events such as mitogen-activated protein kinase (MAPK) activation and IκB phosphorylation. HMGB1 induced an early and sustained activation of the extracellular signal-regulated kinases 1/2 (ERK1/2, p44 and p42) and p38 and of IκB phosphorylation ([Fig. 9](#pone-0065994-g009){ref-type="fig"}). The combination of salbutamol and prednisolone resulted in a partial, but statistically significant inhibition of ERK1 phosphorylation and IκB phosphorylation ([Fig. 9](#pone-0065994-g009){ref-type="fig"}). These data indicate the regulation of HMGB1-mediated cellular signaling by the glucocorticoid/beta-agonist combination has an upstream regulatory component.

![Prednisolone and salbutamol inhibit the HMGB-induced TNFα production.\
RAW 264.7 cells were pretreated with prednisolone (1 µM) and salbutamol (1 µM) and then exposed to HMGB1 (5 µg/ml) for various time up to 18 hours. **A**: TNFα secretion measured in the supernatant is plotted versus exposure length. (MEAN±SD values are shown) **B**: TNFα mRNA expression, normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), is shown as fold expression values of vehicle treated cells. (CTL: vehicle treated control, HMGB: cells exposed to HMGB1, Pred: cells pretreated with prednisolone and exposed to HMGB1, Salb: cells pretreated with salbutamol and exposed to HMGB1, Pred+Salb: cells pretreated with both prednisolone and salbutamol and exposed to HMGB1. ^§^p\<0.05 HMGB1-treated group compared to vehicle treated control, \*p\<0.05 compared to HMGB1 group, ^\#^p\<0.05 compared to single compound treatment).](pone.0065994.g008){#pone-0065994-g008}

![MAPK activation and IκB phosphorylation in response to HMGB1 are ameliorated in synergy by prednisolone and salbutamol.\
**A:** RAW 264.7 cells were exposed to HMGB1 (5 µg/ml) for the indicated length and the phosphorylation of ERK1/2, p38 and IκB was detected. **B:** RAW 264.7 cells pretreated with prednisolone (1 µM) and salbutamol (1 µM) were exposed to HMGB1 (5 µg/ml) for 30 min (ERK1/2, p38) or 1 hour (IκB) and the activation was detected as phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), phospho-p38 (Thr 180) or phospho-IκB-α (Ser 32/36). **C:** Bar graph shows the phosphorylation signal normalized to the total amount of the respective protein. (CTL: vehicle treated control, HMGB: cells exposed to HMGB1, Pred: cells pretreated with prednisolone and exposed to HMGB1, Salb: cells pretreated with salbutamol and exposed to HMGB1, Pred+Salb: cells pretreated with both prednisolone and salbutamol and exposed to HMGB1. ^§^p\<0.05 HMGB1-treated group compared to vehicle treated control, \*p\<0.05 compared to HMGB1 group).](pone.0065994.g009){#pone-0065994-g009}

To further characterize the effect of the glucocorticoid/beta-agonist combination on HMGB1-induced gene transcription, a TLR signaling pathway array was next employed. The responses could be characterized by four distinct expression patterns: **a)** prednisolone, but not salbutamol inhibiting gene expression, **b)** salbutamol, but not prednisolone inhibiting gene expression, **c)** the two compounds synergistically blocking gene expression and **d)** the two compounds synergistically enhancing gene expression ([Fig. 10](#pone-0065994-g010){ref-type="fig"}). The genes which were mostly inhibited by steroids included the interleukins (IL1a, Il1b, IL6, IL10) and Ptgs2 (COX-2); the inhibition exerted by the beta-2 agonist was dominant in case of the chemokines Ccl2 and Cxcl10 and TLR2 and TLR9; synergistic inhibition by the glucocorticoid and the beta-agonist was confirmed for TNFα, as well as demonstrated for lymphotoxin (Lta) and the TLR adaptor Ticam1 ([Fig. 10](#pone-0065994-g010){ref-type="fig"}). Unexpectedly, in a few instances, the steroid and the beta2 agonist led to a synergistic *enhancement*, as seen with Csf3 (GCSF), CD14, CCAAT/enhancer-binding protein beta (Cebpb), interleukin 1 receptor alpha (IL1R1) and TLR8 ([Fig. 10](#pone-0065994-g010){ref-type="fig"}).

![The interaction of prednisolone and salbutamol in the inhibition of HMGB-induced gene expression.\
RAW 264.7 cells pretreated with prednisolone (1 µM) and salbutamol (1 µM) were exposed to HMGB1 (5 µg/ml) for 1.5 hours and the expression of TLR-associated genes was analyzed with TLR signaling pathways array. Gene expression normalized to control genes (GAPDH, actin, B2m, Gusb, Hsp90ab1) is shown as fold expression values of vehicle treated cells. (CTL: vehicle treated control, HMGB: cells exposed to HMGB1, Pred: cells pretreated with prednisolone and exposed to HMGB1, Salb: cells pretreated with salbutamol and exposed to HMGB1, Pred+Salb: cells pretreated with both prednisolone and salbutamol and exposed to HMGB1. ^§^p\<0.05 HMGB1-treated group compared to vehicle treated control, \*p\<0.05 compared to HMGB1 group, ^\#^p\<0.05 compared to single compound treatment).](pone.0065994.g010){#pone-0065994-g010}

Given the fact that both glucocorticoids and beta-receptor agonists represent endogenous hormones of the sympathetic-adrenal-medullary axis, we have next evaluated whether cortisol and/or adrenaline/noradrenaline, at concentrations that are comparable to their endogenous plasma levels, affect HMGB1-induced TNFα production. Cortisol, and, more markedly, the combination of adrenaline and noradrenaline, suppressed the HMGB1-induced TNFα response ([Fig. 11](#pone-0065994-g011){ref-type="fig"}).

![Inhibition of the HMGB-induced inflammatory response by endogenous catecholamines and glucocorticoids at physiological concentrations.\
RAW 264.7 cells were pretreated with cortisol (0.7 µM), noradrenaline (0.5 ng/ml), adrenaline (0.5 ng/ml), dexamethasone (1 µM) and salbutamol (1 µM) and exposed to HMGB1 (5 µg/ml) for 18 hours. TNFα secretion was measured in the supernatant. (^§^p\<0.05 HMGB1-treated group compared to vehicle treated control, \*p\<0.05 compared to HMGB1 group, ^\#^p\<0.05 cells treated with all compounds in combination versus treated with a combination of two.).](pone.0065994.g011){#pone-0065994-g011}

Glucocorticoid/beta-adrenergic Agonist Synergy *in vivo* {#s3e}
--------------------------------------------------------

The combination of prednisolone and salbutamol effectively suppressed HMGB1-induced TNFα production in Balb/c male mice *in vivo*, and this effect was more pronounced than the effect of either agent alone ([Fig. 12](#pone-0065994-g012){ref-type="fig"}). In contrast, the glucocorticoid receptor blocker mifepristone or the β-receptor antagonist propranolol did not enhance HMGB1-induced TNFα production ([Fig. 12](#pone-0065994-g012){ref-type="fig"}), suggesting that the response is not under significant control by endogenous glucocorticoids acting on the mifepristone-sensitive glucocorticoid receptor or by endogenous catecholamines acting on the β-receptor.

![Inhibition of the HMGB-induced TNFα production by catecholamines and glucocorticoids *in vivo*.\
Balb/c male mice (Charles River Laboratories) were injected with 0.5 mg/kg HMGB1 in the presence of 60 min pretreatment of either vehicle, or 20 mg/kg prednisolone, 10 mg/kg salbutamol, the combination of prednisolone and salbutamol (doses as above), or the glucocorticoid receptor blocker mifepristone (30 mg/kg) or the β-receptor antagonist propranolol (10 mg/kg). At 8 hours after HMGB1 injection, animals were sacrificed and serum levels of TNFα were measured. ^\#^p\<0.05 represents a significant increase in TNFα serum levels in response to HMGB1; \*p\<0.05 represents significant inhibition of HMGB1-induced TNFα production by the various pharmacological agents indicated. n = 7 animals per group.](pone.0065994.g012){#pone-0065994-g012}

Discussion {#s4}
==========

It is well established that HMGB1 plays a central role in sterile inflammation [@pone.0065994-Klune1]--[@pone.0065994-Andersson1]. This screen was undertaken to identify inhibitors of HMGB1-induced, TLR4 dependent TNFα production. The hit compounds emerging from the primary screen included several signal transduction pathway modifiers, such as the IκB phosphorylation inhibitor Bay 11-7085 and the Src/Syk kinase inhibitor MNS. These findings are consistent with a role of NF-κB and kinase activation in HMGB1-mediated cellular signaling. Glucocorticoids and beta-receptor agonist activators of intracellular cAMP (such as such as salbutamol, clenbuterol, metaproterenol, ethylnorepinephrine and ritodrine) were two most prominent drug classes emerging from the screen. Because of their therapeutic potential, and because of the endogenous physiological regulatory implications, these two classes of compounds were subject of follow-up studies (see below). Additional classes of hit compounds included the natural compounds, piperlongumine and parthenolide (the latter compound is known pharmacological actions as a NF-κB and MAP kinase inhibitor). The mechanism of action and potential anti-inflammatory utility of miscellaneous additional compounds that showed inhibitory effects - such as the HIV protease inhibitor indinavir, the local anesthetic lidocaine, the surfactant tyloxapol, the calcium antagonist prenylamine and the diuretic ethacrynic acid - requires further characterization. It is interesting to note that indinavir [@pone.0065994-Lagathu1], tyloxapol [@pone.0065994-Ghio1] and lidocaine [@pone.0065994-Lahat1] have previously been demonstrated to suppress TNFα production in various experimental models *in vitro*, although the underlying molecular pathways have not been fully characterized. It is intriguing to speculate that these compounds may have additional, hitherto unrecognized, secondary modes of pharmacological action (as well as potential therapeutic utility) due to inhibition of HMGB1-mediated inflammatory responses.

We identified several different activators of intracellular cAMP signaling as part of the screen for enhancers of the inhibitory effect of glucocorticoids. The enhancers exerted their effects their effects either through beta-adrenergic receptor agonism (such as salbutamol and salmeterol), through prolongation of the intracellular half-life of cAMP (such as the phosphodiesterase inhibitor rolipram) or by activating the cAMP-dependent protein kinase (PKA) (such as prostaglandin E1). While neither the glucocorticoids nor the cAMP-stimulating agents, on their own, produced a complete inhibition of HMGB1-mediated TNFα response, the combination of these two agents yielded a robust inhibition, and did so at low micromolar/nanomolar concentrations. Previous studies have demonstrated synergistic interactions between steroids and beta-agonists in various experimental systems *in vitro* and suggested that cAMP and glucocorticoids act via distinct upstream pathways, which activate transcription though separate hormone response elements, the glucocorticoid receptor (GR) element (GRE) and the cAMP-response element (CRE), respectively. The site of the synergistic convergence was identified at the level of inhibition of the promoter activation of various pro-inflammatory genes [@pone.0065994-Park1]--[@pone.0065994-Colangelo1]. Based on our findings, at least some of the synergistic inhibition of HMGB1-induced signaling by the glucocorticoid/beta-agonist combination occurs upstream from NF-κB activation, upstream from GRE and CRE and upstream from the promoter region of the inflammatory genes studied.

Our analysis of the gene expression profiles using a TLR signaling pathway array demonstrated that the synergistic inhibition of HMGB1-induced TNFα production by the glucocorticoid and the beta agonist does not represent a generalized phenomenon. In the case of several mediators, neither the glucocorticoid tested (e.g. Ccl2, Tlr2, Tlr9, Cd14, Cebpb, Csf3, Tlr8), nor the beta agonist tested (e.g. Il-1a, IL1b, IL6, Csf3, IL1r1) showed any inhibition. In some cases an enhancement was seen (IL1ra, Ptgs2, IL-10). These findings clearly demonstrate that HMGB1-mediated pro-inflammatory mediator production is regulated by glucocorticoids and by cAMP in a fashion that is specific to each gene product, and may be, at least in part, related to individual differences in the steroid and cAMP-responsive elements in individual promoters. Nevertheless, the combination of the beta agonist and the glucocorticoid resulted in a partial suppression for the majority of the genes studied, yielding a shift towards an overall anti-inflammatory phenotype (without suppressing the expression of the anti-inflammatory cytokine IL-10).

HMGB1 signals through numerous receptors, depending upon the molecular conformation of the three cysteines [@pone.0065994-Harris1], [@pone.0065994-Venereau1]--[@pone.0065994-Kim1], [@pone.0065994-Hori1]--[@pone.0065994-Bianchi1]. For example, extracellular HMGB1 is post-translationally regulated via redox mechanisms, and the C23-C45 disulfide C106 thiol conformation binds to and activates the TLR4/MD2 receptor complex in the absence of LPS [@pone.0065994-Venereau1]--[@pone.0065994-Kim1]. Here we utilized this recombinant conformation of HMGB1 (purified and characterized as previously described), which primarily signals through TLR4 to induce TNFα. Because RAGE and TLR2 are dispensable for this effect, our studies would not be expected to address signaling mediated through these receptors.

Hormones of the hypothalamic-pituitary-adrenal axis, the sympathetic-adrenal-medullary axis, and the sympathetic and parasympathetic arms of the autonomic nervous system have powerful roles in the control of inflammation [@pone.0065994-Selye1]--[@pone.0065994-Szabo1]. Adrenalectomy or pharmacological blockade of endogenous glucocorticoid receptors exacerbates [@pone.0065994-Bertini1], while beta-receptor activation suppresses systemic inflammatory responses [@pone.0065994-Szabo1]. Considering the fact that the biologically active concentrations of glucocorticoids and catecholamines in the current study are in the physiological range, we have also explored whether the HMGB1-mediated inflammatory responses are under the tonic control of these hormones. While the combination of exogenous glucocorticoid and beta agonist inhibited HMGB1-induced TNFα production (thereby extending the *in vitro* findings to an *in vivo* system), blockade of the endogenous glucocorticoid receptors with mifepristone or inhibition of the beta receptors with propranolol failed to potentiate the HMGB1-induced TNFα responses *in vivo*. Thus, circulating HMGB1 does not result in a more severe inflammatory response in subjects with impairment of their endogenous sympathetic-adrenal-medullary homeostasis, at least in the current *in vivo* experimental system.

In summary, the current study unveils several drug-like modulators of HMGB1-mediated inflammatory responses and offers pharmacological directions for the therapeutic suppression of inflammatory responses in diseases driven by the HMGB1-TLR4 axis. Glucocorticoids remain a mainstay of therapy for rheumatoid arthritis, as well as many other inflammatory diseases. In rheumatoid arthritis HMGB1 has been shown to play a significant pathogenetic role [@pone.0065994-Harris1], [@pone.0065994-Andersson1]. We hypothesize that the mode of the therapeutic action of glucocorticoids, in addition to inhibiting HMGB1 release [@pone.0065994-Schierbeck1], also involves an inhibition of HMGB1\'s downstream signaling action. Furthermore, we conclude that the synergistic administration of a glucocorticoid and a beta-receptor agonist or (another cAMP-elevating agent) is an effective approach to suppress HMGB1-mediated inflammatory responses *in vitro* and *in vivo*.
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